[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity
Rick A. Carpenter, Chief Technology Officer of Tandem Diabetes Care, reported transactions on 09/15/2025 affecting his holdings of TNDM common stock. 406 restricted stock units (RSUs) vested and were recorded as acquired under code M with a $0 price, leaving 22,773 shares beneficially owned after the transaction. Separately, 207 shares were disposed of under code F(1) at $12.09 per share, leaving 22,566 shares reported as beneficially owned following that disposition. The filing states that the Company withheld shares to satisfy tax withholding on RSU vesting and that no shares were sold to cover taxes. The RSUs were originally awarded on 12/15/2021 under the 2013 Stock Incentive Plan and vest 25% on 12/15/2022 with the remainder vesting in twelve equal quarterly installments.
Rick A. Carpenter, Chief Technology Officer di Tandem Diabetes Care, ha riportato operazioni il 15/09/2025 che influenzano le sue partecipazioni in azioni ordinarie TNDM. 406 RSU (unità di azioni vincolate) si sono maturate e sono state registrate come acquisite con codice M a prezzo di 0$, lasciando 22.773 azioni detentute beneficiariamente dopo la transazione. Invece, 207 azioni sono state alienate sotto il codice F(1) a 12,09$ per azione, lasciando 22.566 azioni riportate come detenute beneficiariamente a seguito di quella cessione. La dichiarazione indica che la Società ha trattenuto azioni per soddisfare le ritenute fiscali sull vesting delle RSU e che non sono state vendute azioni per coprire le tasse. Le RSU erano originariamente assegnate il 15/12/2021 ai sensi del 2013 Stock Incentive Plan e maturano il 25% il 15/12/2022 con il resto che matura in dodici rate trimestrali uguali.
Rick A. Carpenter, Director Tecnológico de Tandem Diabetes Care, reportó transacciones el 15/09/2025 que afectan sus participaciones en acciones comunes TNDM. 406 RSU (unidades de acciones restringidas) se adquirieron y se registraron como adquiridas bajo el código M con un precio de $0, dejando 22,773 acciones poseídas de forma beneficiosa tras la operación. Separadamente, 207 acciones se dispositionaron bajo el código F(1) a $12.09 por acción, dejando 22,566 acciones reportadas como poseídas de forma beneficiosa tras esa disposición. El documento indica que la compañía retuvo acciones para satisfacer las retenciones fiscales sobre el vesting de RSU y que no se vendieron acciones para cubrir impuestos. Las RSU fueron originalmente otorgadas el 15/12/2021 bajo el Plan de Incentivos de Acciones de 2013 y el vesting es del 25% el 15/12/2022, con el resto vesting en doce cuotas trimestrales iguales.
Rick A. Carpenter는 Tandem Diabetes Care의 최고기술책임자로, 2025년 9월 15일에 TNDM 보통주 보유에 영향을 미치는 거래를 보고했습니다. 406 RSU(제한 주식 단위)가 취득으로 귀속되었고 M 코드로 기록되며 가격은 $0였습니다. 그로 인해 22,773주를 실질 보유 주식으로 남겼습니다. 별도로 207주가 F(1) 코드로 $12.09에 처분되어, 그 처분 후 22,566주가 실질 보유 주식으로 보고되었습니다. 제출 문서에 따르면 회사는 RSU 귀속에 따른 세금 원천징수를 충당하기 위해 주식을 보유했고, 세금을 충당하기 위해 매각은 없었다고 명시하고 있습니다. RSU는 원래 2021년 12월 15일에 2013 주식 보상 계획 아래 수여되었으며, 2022년 12월 15일에 25%가 귀속되고 나머지는 12개 분할로 매분기 귀속됩니다.
Rick A. Carpenter, Directeur Technique de Tandem Diabetes Care, a déclaré des opérations le 15/09/2025 affectant ses participations en actions ordinaires TNDM. 406 RSU (unités d’actions restreintes) se sont acquises et ont été enregistrées comme acquises sous le code M avec un prix de 0 $, laissant 22 773 actions détenues bénéficiairement après la transaction. Separément, 207 actions ont été disposées sous le code F(1) à 12,09 $ par action, laissant 22 566 actions rapportées comme détenues bénéficiairement suite à cette cession. Le dossier indique que la société a retenu des actions pour satisfaire les retenues d’impôt sur le vesting des RSU et qu’aucune action n’a été vendue pour couvrir les impôts. Les RSU avaient été attribuées initialement le 15/12/2021 dans le cadre du Plan d’Incitation à l’Action de 2013 et le vesting est de 25 % le 15/12/2022, le reste vestant en douze versements trimestriels égaux.
Rick A. Carpenter, Chief Technology Officer von Tandem Diabetes Care, meldete Transaktionen am 15.09.2025, die seine Beteiligungen an TNDM Stammaktien betreffen. 406 RSUs (Restricted Stock Units) wurden vesting und als erworben unter dem Code M mit einem Preis von 0 $ verbucht, wodurch nach der Transaktion 22.773 Aktien wirtschaftlich beteiligt bleiben. Zusätzlich wurden 207 Aktien unter dem Code F(1) zu 12,09 $ pro Aktie veräußert, verbleibend 22.566 Aktien als wirtschaftlich beteiligt nach dieser Veräußerung. Die Einreichung besagt, dass das Unternehmen Aktien einbehalten hat, um Steuerrückstellungen auf RSU-Vesting zu erfüllen, und dass keine Aktien verkauft wurden, um Steuern zu decken. Die RSUs wurden ursprünglich am 15.12.2021 gemäß dem 2013 Stock Incentive Plan gewährt und vesten zu 25% am 15.12.2022, der Rest vestet in zwölf gleichen vierteljährlichen Raten.
Rick A. Carpenter، المدير التنفيذي للتقنية في Tandem Diabetes Care، أبلغ عن معاملات في 15/09/2025 تؤثر على حصصه من الأسهم العادية TNDM. 406 RSU (وحدات الأسهم المحدودة) استحقت وتُسجل كمكتسبة تحت الرمز M بسعر $0، مما ترك 22,773 سهمًا مملوكًا لفائدة بعد الصفقة. بشكل منفصل، تم التخلي عن 207 أسهم تحت الرمز F(1) بسعر $12.09 للسهم، مما ترك 22,566 سهمًا مبلَّغًا عنه كمملوك لفائدة بعد ذلك التصرف. تنص الإفادة على أن الشركة احتجزت أسهم لتلبية خصومات الضرائب على استحقاق RSU وأنه لم تُبع أي أسهم لتغطية الضرائب. تم منح RSU أصلاً في 15/12/2021 بموجب خطة حوافز الأسهم لعام 2013 وتستحق 25% في 15/12/2022 مع استكمال الاستحقاق على مدى اثنتي عشرة دفعة ربع سنوية متساوية.
Rick A. Carpenter，Tandem Diabetes Care 的首席技术官，已报告在 2025-09-15 的交易，涉及其 TNDM 普通股持有。406个受限股票单位（RSU）已归属并按 M 代码记录为取得，价格为 $0，交易后实际持有股数为 22,773 股。另有 207 股按 F(1) 代码以每股 $12.09 进行处置，处置后报告实际持有的股数为 22,566 股。 filings 声明公司扣留股票以满足 RSU 归属的税款预扣，未出售股票以覆盖税款。RSU 于 2021-12-15 最初授予，依据 2013 年股票激励计划，计划在 2022-12-15 实现 25% 的归属，其余部分按等分的十二个季度分期归属。
- RSU vesting recorded (406 RSUs) indicating routine compensation rather than opportunistic selling
- Tax withholding via share retention rather than open-market sales, as disclosed in the filing
- Disposition of 207 shares at $12.09 reduced reported beneficial ownership modestly
Insights
TL;DR: Insider received RSU vesting and a small disposition; overall ownership change is immaterial to company valuation.
The report documents routine compensation-related activity: vesting of 406 RSUs and a related disposition of 207 shares at $12.09 per share, with share withholding used to satisfy taxes rather than a cash sale. The net change in reported beneficial ownership is modest (from documented figures), and there is no indication of large-scale selling pressure or material dilution beyond standard employee compensation mechanics. For investors, this is a standard insider compensation event rather than a signal of operational or financial change.
TL;DR: Disclosure aligns with Section 16 reporting rules and internal compensation plans; documentation is complete.
The Form 4 clearly identifies the reporting person, relationship (Chief Technology Officer), transaction dates, codes (M for RSU vesting and F(1) for disposition), and explains tax-withholding treatment. The filing references the 2013 Stock Incentive Plan and the original award date (12/15/2021), and includes vesting schedule language. The signature is provided by an attorney-in-fact, meeting procedural requirements. There are no governance red flags or missing required disclosures in the provided content.
Rick A. Carpenter, Chief Technology Officer di Tandem Diabetes Care, ha riportato operazioni il 15/09/2025 che influenzano le sue partecipazioni in azioni ordinarie TNDM. 406 RSU (unità di azioni vincolate) si sono maturate e sono state registrate come acquisite con codice M a prezzo di 0$, lasciando 22.773 azioni detentute beneficiariamente dopo la transazione. Invece, 207 azioni sono state alienate sotto il codice F(1) a 12,09$ per azione, lasciando 22.566 azioni riportate come detenute beneficiariamente a seguito di quella cessione. La dichiarazione indica che la Società ha trattenuto azioni per soddisfare le ritenute fiscali sull vesting delle RSU e che non sono state vendute azioni per coprire le tasse. Le RSU erano originariamente assegnate il 15/12/2021 ai sensi del 2013 Stock Incentive Plan e maturano il 25% il 15/12/2022 con il resto che matura in dodici rate trimestrali uguali.
Rick A. Carpenter, Director Tecnológico de Tandem Diabetes Care, reportó transacciones el 15/09/2025 que afectan sus participaciones en acciones comunes TNDM. 406 RSU (unidades de acciones restringidas) se adquirieron y se registraron como adquiridas bajo el código M con un precio de $0, dejando 22,773 acciones poseídas de forma beneficiosa tras la operación. Separadamente, 207 acciones se dispositionaron bajo el código F(1) a $12.09 por acción, dejando 22,566 acciones reportadas como poseídas de forma beneficiosa tras esa disposición. El documento indica que la compañía retuvo acciones para satisfacer las retenciones fiscales sobre el vesting de RSU y que no se vendieron acciones para cubrir impuestos. Las RSU fueron originalmente otorgadas el 15/12/2021 bajo el Plan de Incentivos de Acciones de 2013 y el vesting es del 25% el 15/12/2022, con el resto vesting en doce cuotas trimestrales iguales.
Rick A. Carpenter는 Tandem Diabetes Care의 최고기술책임자로, 2025년 9월 15일에 TNDM 보통주 보유에 영향을 미치는 거래를 보고했습니다. 406 RSU(제한 주식 단위)가 취득으로 귀속되었고 M 코드로 기록되며 가격은 $0였습니다. 그로 인해 22,773주를 실질 보유 주식으로 남겼습니다. 별도로 207주가 F(1) 코드로 $12.09에 처분되어, 그 처분 후 22,566주가 실질 보유 주식으로 보고되었습니다. 제출 문서에 따르면 회사는 RSU 귀속에 따른 세금 원천징수를 충당하기 위해 주식을 보유했고, 세금을 충당하기 위해 매각은 없었다고 명시하고 있습니다. RSU는 원래 2021년 12월 15일에 2013 주식 보상 계획 아래 수여되었으며, 2022년 12월 15일에 25%가 귀속되고 나머지는 12개 분할로 매분기 귀속됩니다.
Rick A. Carpenter, Directeur Technique de Tandem Diabetes Care, a déclaré des opérations le 15/09/2025 affectant ses participations en actions ordinaires TNDM. 406 RSU (unités d’actions restreintes) se sont acquises et ont été enregistrées comme acquises sous le code M avec un prix de 0 $, laissant 22 773 actions détenues bénéficiairement après la transaction. Separément, 207 actions ont été disposées sous le code F(1) à 12,09 $ par action, laissant 22 566 actions rapportées comme détenues bénéficiairement suite à cette cession. Le dossier indique que la société a retenu des actions pour satisfaire les retenues d’impôt sur le vesting des RSU et qu’aucune action n’a été vendue pour couvrir les impôts. Les RSU avaient été attribuées initialement le 15/12/2021 dans le cadre du Plan d’Incitation à l’Action de 2013 et le vesting est de 25 % le 15/12/2022, le reste vestant en douze versements trimestriels égaux.
Rick A. Carpenter, Chief Technology Officer von Tandem Diabetes Care, meldete Transaktionen am 15.09.2025, die seine Beteiligungen an TNDM Stammaktien betreffen. 406 RSUs (Restricted Stock Units) wurden vesting und als erworben unter dem Code M mit einem Preis von 0 $ verbucht, wodurch nach der Transaktion 22.773 Aktien wirtschaftlich beteiligt bleiben. Zusätzlich wurden 207 Aktien unter dem Code F(1) zu 12,09 $ pro Aktie veräußert, verbleibend 22.566 Aktien als wirtschaftlich beteiligt nach dieser Veräußerung. Die Einreichung besagt, dass das Unternehmen Aktien einbehalten hat, um Steuerrückstellungen auf RSU-Vesting zu erfüllen, und dass keine Aktien verkauft wurden, um Steuern zu decken. Die RSUs wurden ursprünglich am 15.12.2021 gemäß dem 2013 Stock Incentive Plan gewährt und vesten zu 25% am 15.12.2022, der Rest vestet in zwölf gleichen vierteljährlichen Raten.
FAQ
What transactions did Rick A. Carpenter report for TNDM on 09/15/2025?
How many TNDM shares does Rick Carpenter beneficially own after these transactions?
Were any shares sold on the open market to cover taxes for the vested RSUs?
What is the origin and vesting schedule of the RSUs reported?
Who signed the Form 4 filing for Rick Carpenter?
